Hostname: page-component-586b7cd67f-rcrh6 Total loading time: 0 Render date: 2024-12-01T09:06:37.714Z Has data issue: false hasContentIssue false
  • English
  • Français

SHORTENED PEGINTERFERON AND RIBAVIRIN TREATMENT FOR CHRONIC HEPATITIS C

Published online by Cambridge University Press:  21 September 2012

Debbie Hartwell ,
Jeremy Jones ,
Louise Baxter  and
Jonathan Shepherd
Debbie Hartwell
Affiliation:
e-mail: [email protected]
Jeremy Jones
Affiliation:
Southampton Health Technology Assessments Centre (SHTAC), University of Southampton, First Floor Epsilon House, Enterprise Road, Southampton Science Park, Southampton SO16 7NS
Louise Baxter
Affiliation:
Southampton Health Technology Assessments Centre (SHTAC), University of Southampton, First Floor Epsilon House, Enterprise Road, Southampton Science Park, Southampton SO16 7NS
Jonathan Shepherd
Affiliation:
Southampton Health Technology Assessments Centre (SHTAC), University of Southampton, First Floor Epsilon House, Enterprise Road, Southampton Science Park, Southampton SO16 7NS
Get access Rights & Permissions [Opens in a new window]

Abstract

Background: Peginterferon alfa and ribavirin combination therapy is an effective treatment for many patients with chronic hepatitis C virus (HCV). Reducing the length of treatment may be advantageous. We performed a systematic review and economic evaluation to assess shorter treatment duration of this regimen.

Methods: We searched fourteen bibliographic databases (including The Cochrane Library, Medline, and Embase) from 2000 to October 2009 and consulted experts and drug manufacturers. Eligible articles were randomized controlled trials (RCTs) selected according to predefined criteria. We undertook an economic evaluation to assess the cost-effectiveness of shortened treatment versus standard treatment in the UK.

Results: Six trials were included. In the sub-group of patients who had low viral load (LVL) and a rapid virological response (RVR), there were no statistically significant differences in sustained virological response (SVR) rates between patients who received standard treatment (range, 83 percent to 100 percent) and those who received shortened courses (range 84 percent to 96 percent) (24 weeks for genotype 1, 16 weeks for genotype 2/3). Shortened treatment resulted in cost savings, but in some scenarios also resulted in poorer outcome, compared with standard treatment. This requires a judgment to be made on the value of the quality-adjusted life-year loss resulting from adopting a shorter treatment regimen, if shorter treatment is associated with a lower SVR than standard treatment duration.

Conclusions: For chronic HCV patients who have LVL and achieve an RVR, shortened peginterferon and ribavirin combination therapy could be considered as a viable treatment option.

Keywords

Chronic hepatitis CCost-effectivenessEconomic evaluationPeginterferon alfaSystematic review
Type
ASSESSMENTS
Information
International Journal of Technology Assessment in Health Care , Volume 28 , Issue 4 , October 2012 , pp. 398 - 406
Copyright
Copyright © Cambridge University Press 2012

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Berg, T, Weich, V, Teuber, G, et al.Individualized treatment strategy according to early viral kinetics in hepatitis C virus type 1-infected patients. Hepatology. 2009;50:369–377.CrossRefGoogle ScholarPubMed
2.Centre for Reviews and Dissemination (CRD). Systematic reviews: CRD's guidance for undertaking reviews in health care (3rd ed). York: York Publishing Services Ltd; 2009.Google Scholar
3.Curtis, L.Unit costs of health and social care. Canterbury: Personal Social Services Research Unit, University of Kent; 2008.Google Scholar
4.de Bruijne, J, Buster, EHCJ, Gelderblom, HC, et al.Treatment of chronic hepatitis C virus infection - Dutch national guidelines. Neth J Med. 2008;66:311–322.Google ScholarPubMed
5.Dolan, P, Gudex, C, Kind, P, Williams, A. A social tariff for EuroQol: Results from a UK general population survey. Discussion Paper 138. York: Centre for Health Economics, University of York; 1995.Google Scholar
6.Foster, GR, Goldin, RD, Main, J, et al.Management of chronic hepatitis C: Clinical audit of biopsy based management algorithm. BMJ. 1997;315:453–458.CrossRefGoogle ScholarPubMed
7.Ghany, MG, Strader, DB, Thomas, DL, Seeff, LB. Diagnosis, management, and treatment of Hepatitis C: An update. Hepatology. 2009;49:1335–1374.CrossRefGoogle ScholarPubMed
8.Hartwell, D, Jones, J, Baxter, L, Shepherd, J. Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: A systematic review and economic evaluation. Health Technol Assess. 2011;15:1–204.CrossRefGoogle ScholarPubMed
9.Hartwell, D, Shepherd, J. Pegylated and non-pegylated interferon-alfa and ribavirin for the treatment of mild chronic hepatitis C: A systematic review and meta-analysis. Int J Technol Assess Health Care. 2009;25:56–62.CrossRefGoogle ScholarPubMed
10.Higgins, JPT, Altman, DT. Assessing risk of bias in included studies. In: Higgins, JPT, Altman, DT, eds. Cochrane handbook for systematic reviews of interventions. Version 5.0.1 (updated September 2008). The Cochrane Collaboration; 2008.CrossRefGoogle Scholar
11.Liu, C-H, Liu, C-J, Lin, C, et al.Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: A multicenter, randomized controlled trial. Clin Infect Dis. 2008;47:1260–1269.CrossRefGoogle ScholarPubMed
12.Longworth, L, Young, T, Ratcliffe, J, Bryan, S, Buxton, M. Economic evaluation of the Transplantation Programme in England and Wales: An assessment of the costs of liver transplantation. Unpublished Report to the Department of Health; 2001.Google Scholar
13.Mangia, A, Minerva, N, Bacca, D, et al.Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial. Hepatology. 2008;47:43–50.CrossRefGoogle ScholarPubMed
14.Mohsen, AH, Trent HCV Study Group. The epidemiology of hepatitis C in a UK health regional population of 5.12 million. Gut. 2001;48:707–713.CrossRefGoogle Scholar
15.National Institute for Health and Clinical Excellence (NICE). Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C. Technology Appraisal Guidance No 75. London: NICE; 2004.Google Scholar
16.National Institute for Health and Clinical Excellence (NICE). Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C. Technology Appraisal Guidance No 106. London: NICE; 2006.Google Scholar
17.National Institute for Health and Clinical Excellence (NICE). Guide to the methods of technology appraisal. http://www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatesJune2008.pdf. London: NICE; 2008 (accessed August, 2009).Google Scholar
18.National Institute for Health and Clinical Excellence (NICE). Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C: Part-review of NICE technology appraisal guidance TA75 and TA106. Technology Appraisal Guidance No 200. London: NICE; 2010.Google Scholar
19.Shepherd, J, Brodin, HFT, Cave, CB, et al.Clinical- and cost-effectiveness of pegylated interferon alfa in the treatment of chronic hepatitis C: A systematic review and economic evaluation. Int J Technol Assess Health Care. 2005;21:47–54.CrossRefGoogle ScholarPubMed
20.Shepherd, J, Jones, J, Hartwell, D, et al.Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: A systematic review and economic evaluation. Health Technol Assess. 2007;11:1–205.CrossRefGoogle ScholarPubMed
21.Stinnett, AA, Mullahy, J. Net health benefits: A new framework for the analysis of uncertainty in cost effectiveness analysis. Med Decis Making. 2009;18:S68–S80.CrossRefGoogle Scholar
22.Tambour, M, Zethraeus, N, Johannesson, M. A note on confidence intervals in cost effectiveness analysis. Int J Technol Assess Health Care. 1998;14:467–471.CrossRefGoogle ScholarPubMed
23.The Global Burden Of Hepatitis C Working Group. Global burden of disease (GBD) for hepatitis C. J Clin Pharmacol. 2004;44:20–29.CrossRefGoogle Scholar
24.Thomson, BJ, Finch, RG. Hepatitis C virus infection. Clin Microbiol Infect. 2005;11:86–94.CrossRefGoogle ScholarPubMed
25.von Wagner, M, Huber, M, Berg, T, et al.Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology. 2005;129:522–527.CrossRefGoogle ScholarPubMed
26.Wright, M, Grieve, R, Roberts, J, et al.Health benefits of antiviral therapy for mild chronic hepatitis C: Randomised controlled trial and economic evaluation. Health Technol Assess. 2006;10:1–113.CrossRefGoogle ScholarPubMed
27.Yu, M, Dai, C, Huang, J, et al.Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: A randomized trial. Hepatology. 2008;47:1884–1893.CrossRefGoogle ScholarPubMed
28.Yu, M, Dai, C, Huang, J, et al.A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. Gut. 2007;56:553–559.CrossRefGoogle ScholarPubMed
Supplementary material: File

Hartwell et al. supplementary material

Appendix

Download Hartwell et al. supplementary material(File)
File 30.7 KB
Supplementary material: File

Hartwell et al. supplementary material

Supplementary table 1

Download Hartwell et al. supplementary material(File)
File 32.8 KB
Supplementary material: File

Hartwell et al. supplementary material

Supplementary table 2

Download Hartwell et al. supplementary material(File)
File 30.7 KB
Supplementary material: File

Hartwell et al. supplementary material

Supplementary table 3

Download Hartwell et al. supplementary material(File)
File 87 KB
Supplementary material: File

Hartwell et al. supplementary material

Supplementary table 4

Download Hartwell et al. supplementary material(File)
File 50.7 KB